Custom-made mRNA (GMP)

# Scope The Department of Medical BioSciences from Radboudumc has been awarded a KWF grant for the PROTECT-lynch study. The main goal of the PROTECT-lynch study is a new treatment option for LS patients significantly improving the quality of life of LS patients and most likely the prognosis (occurrence of Lynch-related cancer(s). Standard care for healthy LS patients currently consists of undergoing intensive surveillance programs that do not guarantee timely detection of one or more Lynch-related cancers at a treatable stage. The PROTECT-lynch study may change this with its preventive dendritic cell therapy. To prepare the intended dendritic cell (DC) product for the PROTECT-lynch study - mRNA coding for carcinoembryonic antigen (CEA) is required in GMP quality. As the Medical BioSciences...